Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma

Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Immunotherapy of Hepatocellular Carcinoma: Recent Progress and New Strategy.

Research progress of chimeric antigen receptor NK cells in hepatocellular carcinoma

New advances in the treatment of intermediate and advanced hepatocellular carcinoma

A long way to the battlefront: CAR T cell therapy against solid cancers.

Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments

Current progress in CAR-T cell therapy for tumor treatment

Therapeutic advances in hepatocellular carcinoma: an update from the 2024 ASCO annual meeting

Recent treatments to Hepatocellular Carcinoma Cancer(HCC): update and outlook

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment